DexCom Inc (DXCM) reports strong international growth and expanding customer base, while facing margin pressures and US ...

Dexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access.

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and ...

DexCom, Inc. DXCM reported fourth-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which missed the Zacks ...

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

Stifel Nicolaus analyst Mathew Blackman reiterated a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

Barclays analyst Matt Miksic lowered the firm’s price target on DexCom (DXCM) to $90 from $92 and keeps an Equal Weight rating on the shares.